SPOTLIGHT -
Urologist David Morris, MD, FACS, shares his perspective on communicating cardiovascular risk to patients starting androgen deprivation therapy.
Minimizing incontinence after radical prostatectomy: Lessons learned
"I've worked in 3 different countries, I've seen dozens of people doing robotic radical prostatectomy...so my current practice is kind of a “best of” what I have seen and learned," says Ricardo Soares, MD.
Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer
Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.
Hormone therapy plus current treatments improves survival in prostate cancer
Darolutamide increased overall survival compared to placebo in the overall patient population and patients with high-volume, high-risk mHSPC as well as in patients with low-risk metastatic hormone-sensitive prostate cancer.
Dr. Laviana on decisional regret after prostate cancer treatment
“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.
Enzalutamide plus leuprolide boosts metastasis-free survival in nmHSPC
The enzalutamide/leuprolide combo also led to statistically significant improvements in time to PSA progression and time to start of new antineoplastic therapy.
ProtecT trial researchers: Active monitoring yields same outcomes as radical treatment in prostate cancer
Findings suggest many patients with localized disease can delay surgery or radiation without increasing their mortality risk.